NCT05630989View on ClinicalTrials.gov

A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

RecruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

February 7, 2023

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2027

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
OTHER

combination therapy with no MEKi

This cohort will receive combination therapy with no MEKi.

DRUG

combination therapy with MEKi-HCQ

This cohort will receive combination therapy with MEKi-HCQ.

DRUG

combination therapy with MEKi-EGFRi

This cohort will receive combination therapy with MEKi-EGFRi.

DRUG

combination therapy with MEKi.

This cohort will receive combination therapy with MEKi.

Trial Locations (1)

53226

RECRUITING

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

All Listed Sponsors
lead

Mandana Kamgar, MD

OTHER